Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer

Cancer 2026 Open access

Read full text
Authors: Maria J Monroy-Iglesias, Kelli O'Connell, Jenna Bhimani, Victoria S. Blinder, Rachael P. Burganowski-Doud, Isaac Joshua Ergas, Grace B Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke
+13 more Cecile A Laurent, Raymond Liu, Kanichi G. Nakata, Sonia Persaud, Janise M. Roh, Yashasvini Sampathkumar, Sara M. Tabatabai, Emily Valice, Peng Wang, Erin J. Aiello Bowles, Elisa Victoria Bandera, L. Kushi, Elizabeth D. Kantor
DOI: 10.1002/cncr.70294
Cited by: 1
References: 42

Abstract

BACKGROUND: For most cytotoxic drugs, guidelines recommend body-surface-area-based dosing, yet some patients start with reduced doses, potentially reflecting tolerability concerns. The relationship between first-cycle dose reductions and subsequent delivery is unclear. METHODS: The authors analyzed data from women with stage I-IIIA breast cancer treated with adjuvant chemotherapy. Sankey diagrams illustrated trajectories from first-cycle dose proportion (FCDP) to average relative dose intensity (ARDI, ratio of received to expected dose intensity across the regimen), and cumulative dose proportion (CDP, ratio of total received to expected dose). Poisson regression estimated adjusted prevalence ratios for reduced FCDP (

Fields of Study & Subjects

Breast Cancer Treatment Studies Cancer Treatment and Pharmacology Cancer Risks and Factors

Publication details

Journal / source
Cancer
Publisher
Wiley
Volume
132
Issue
5
Pages
e70294–e70294
Publication date
24 February 2026
Language
EN